In Mexico, between May 2 and yesterday, June 7, the records of active cases of the Covid-19 disease went from 5,201 to 23,410; the figures indicate an increase in infections of the SARS-CoV-2 virus of 350 percent.
According to official information from the Ministry of Health of the federal government, from April 17 to 30, the incidence rate of active cases was 4 per 100,000 inhabitants.
While the incidence rate of active cases until yesterday was 18 per 100,000 inhabitants, specifies the Covid-19 Mexico Weekly Technical Report, issued this Tuesday.
Until yesterday, Baja California Sur, Mexico City, Sinaloa, Yucatán, Quintana Roo, Colima, Aguascalientes, Nuevo León, Nayarit and Baja California, in strict order, occupied the first 10 places in terms of the rate of active cases per 100,000 inhabitants. by federal entity.
As of May 2, the record of total deaths from Covid-19 amounted to 324,334, while yesterday they added 325,042 cases, that is, the period added 708 more deaths.
infections will continue
Given the increase in cases of Covid-19 and the return of daily reports, the Undersecretary of Health, Hugo López-Gatell, said that SARS-CoV-2 “is going to stay forever”, although now it is a disease with less damage capacity, but more transmissibility.
“It goes from being a high-damage disease to a disease with little capacity to cause greater damage. There are going to start to be some waves that are going to increasingly enter a seasonal phase, most likely between October and March,” he indicated.
Vaccines for minors
On the other hand, the anti-Covid Abdala vaccine, created by Cuba and applied to minors, is still under analysis at the Federal Commission for the Protection against Sanitary Risks (Cofepris), but “we no longer have any doubts about its quality and safety,” he said. Lopez-Gatell.
“We need some additional pieces that the Cuban government has and the form of presentation had not been clear,” he added.
Regarding Pfizer, he indicated that the negotiation with the pharmaceutical company continues for the acquisition of doses that are contemplated for children from 5 to 11 years of age, but have not yet materialized.